Log in

Relevant bibliographies by topics / Sodium-glucose cotransporter type 2 inhibitor / Journal articles

To see the other types of publications on this topic, follow the link: Sodium-glucose cotransporter type 2 inhibitor.

Journal articles on the topic 'Sodium-glucose cotransporter type 2 inhibitor'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Sodium-glucose cotransporter type 2 inhibitor.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Petunina, N. A., E. V. Goncharova, M. Е. Теlnova, I. A. Kuzina, N. S. Martirosyan, and A. Yu Sochneva. "Modern inhibitor of sodium-glucose cotransporter type 2 – ertugliflozin." Meditsinskiy sovet = Medical Council, no. 6 (May 12, 2023): 234–40. http://dx.doi.org/10.21518/ms2022-032.

Full text

Abstract:

Diabetes mellitus, a well-known risk of cardiovascular disease (CVD), in patients with type 2 diabetes mellitus (DM2) Hyperglycemia has been found to be an increased risk of coronary heart disease and mortality. In real clinical practice, physicians are faced with the problem of choice when prescribing new hypoglycemic drugs in patients with type 2 diabetes and high cardiovascular risk. Modern possibilities and approaches to the treatment of DM2 have contributed to the creation of a promising class of hypoglycemic drugs that block renal glucose reabsorption - inhibitors of the sodium-glucose c

APA, Harvard, Vancouver, ISO, and other styles

2

Klinkner, Gwen, and Maggie Steingraber-Pharr. "Euglycemic Diabetic Ketoacidosis Associated With SGLT2 Inhibitor Therapy: A Case Report." AACN Advanced Critical Care 34, no. 1 (2023): 27–32. http://dx.doi.org/10.4037/aacnacc2023830.

Full text

Abstract:

Sodium-glucose cotransporter-2 inhibitors are now considered second-line treatment agents for type 2 diabetes and offer a unique treatment approach with added cardiorenal benefits. Drugs in this class increase the risk of euglycemic diabetic ketoacidosis, which may be difficult to diagnose if clinicians are not aware of the risk factors and subtle symptoms. This article describes a case of euglycemic diabetic ketoacidosis in a patient with coronary artery disease who was taking a sodium-glucose cotransporter-2 inhibitor and experienced acute mental status changes immediately after heart cathet

APA, Harvard, Vancouver, ISO, and other styles

3

Hendryx, Michael, Yi Dong, Jonas M. Ndeke, and Juhua Luo. "Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis." PLOS ONE 17, no. 9 (2022): e0274519. http://dx.doi.org/10.1371/journal.pone.0274519.

Full text

Abstract:

Introduction Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a relatively new class of antidiabetic drugs. Emerging findings from laboratory studies indicate that SGLT2 inhibitors can improve liver function and suppress the proliferation of hepatocellular carcinoma (HCC) cells. The aim of this study was to test the hypothesis that initiation of SGLT2 inhibitors improves HCC prognosis in a human population. Methods We used National Surveillance, Epidemiology and End Results (SEER)—Medicare linked data in the United States to evaluate the role of SGLT2 inhibitor initiation on the survival

APA, Harvard, Vancouver, ISO, and other styles

4

Martha Lilac Ketisha Antoine, Malyn, and Yancheng Xu. "Sodium-glucose cotransporter-2 inhibitors: current knowledge on the use of canagliflozin, dapagliflozin and empagliflozin in the treatment of type 2 diabetes mellitus." International Journal of Medicine 8, no. 1 (2020): 8. http://dx.doi.org/10.14419/ijm.v8i1.30308.

Full text

Abstract:

Sodium-glucose cotransporter-2 inhibitors are considered the newest class of medication developed for the treatment of type 2 diabetes mellitus. This class of drug reduces blood glucose levels by decreasing glucose absorption at the level of the kidneys. Through their mechanism of action, drugs within this class exhibit the ability to reduce blood pressure, fasting blood glucose and body weight. The common side effects observed with the use of sodium-glucose cotransporter-2 inhibitors include: genital mycotic infections, intravascular volume depletion and dehydration. To date, much is already

APA, Harvard, Vancouver, ISO, and other styles

5

Kelemen, Hajnal, Petra-Edina Mărcuțiu, and Adrienn Rausz. "New oral antidiabetics – pharmaceutical chemical characterization of sodium-glucose cotransporter-2 inhibitors." Bulletin of Medical Sciences 96, no. 1 (2023): 107–23. https://doi.org/10.2478/orvtudert-2023-0009.

Full text

Abstract:

Abstract Selective sodium-glucose cotransporter-2 (SGLT-2) inhibitors represent a novel, innovative class of oral antidiabetic agents for the treatment of type 2 diabetes. The first sodium-glucose transporter (SGLT) inhibitor to be discovered was a naturally occurring O-glycoside, phlorizin, which is found in a number of plants, including the bark of the apple tree root. Although it can lower blood glucose levels, it is not used for this purpose because it is not a selective inhibitor. The structure of the lead molecule, phlorizin, has been further developed into the SGLT-2 inhibitors that are

APA, Harvard, Vancouver, ISO, and other styles

6

Mishra, Rahul, Ghada Elshimy, Lakshmi Kannan, and Rishi Raj. "Sodium–glucose cotransporter 2 inhibitor-associated severe epididymo-orchitis." BMJ Case Reports 15, no. 7 (2022): e250942. http://dx.doi.org/10.1136/bcr-2022-250942.

Full text

Abstract:

A man in his late 50s, with uncontrolled type 2 diabetes mellitus (T2DM) and morbid obesity, presented to the hospital with complicated epididymo-orchitis. The onset of symptoms (scrotal pain, erythema and swelling) occurred after the use of empagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, for 2 months. His baseline antidiabetic medications were insulin, glipizide and metformin. Initially, he had failed treatment of epididymo-orchitis with oral levofloxacin for 3 weeks, followed by 2 weeks of doxycycline therapy. At the presentation to the hospital, an ultrasound of the scrot

APA, Harvard, Vancouver, ISO, and other styles

7

Alipour, Meysam, Jalal Rezaei, Venus Shahabi Rabori, et al. "Limb amputation following sodium-glucose cotransporter type 2 inhibitor therapy." Journal of Preventive Epidemiology 10, no. 1 (2024): e38251. https://doi.org/10.34172/jpe.2025.38251.

Full text

Abstract:

This review article examines the association between sodium-glucose cotransporter type 2 inhibitors (SGLT2i) and the risk of limb amputation, particularly in patients with type 2 diabetes mellitus. This review aims to provide a comprehensive understanding of the risks associated with SGLT2i therapy and to inform future research directions in this area. While SGLT2i medications, such as canagliflozin, are recognized for their cardiovascular and renal benefits, emerging evidence suggests a potential increase in the risk of lower limb amputations (LLAs) among users compared to non-users of SGLT2i

APA, Harvard, Vancouver, ISO, and other styles

8

Hamza Shabbir, Muhammad Rasikh, Khalid Bashir, et al. "Impact of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors on Cardiovascular Events in Type 2 Diabetes." Indus Journal of Bioscience Research 3, no. 1 (2025): 320–24. https://doi.org/10.70749/ijbr.v3i1.496.

Full text

Abstract:

Introduction: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder marked by persistent hyperglycemia and insulin resistance. Objective: The main objective of the study is to find the impact of Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors on cardiovascular events in Type 2 diabetes. Methodology: This randomized control trial was conducted at Shalamar Hospital, Lahore, from 1st March to 31st August 2024. Data were collected from 195 patients. Data were collected at baseline and subsequent follow-up visits through standardized protocols. Results: Data were collected from 195 pati

APA, Harvard, Vancouver, ISO, and other styles

9

Faizan, Khorajiya* Dr. Khushbu Patel Khushbu Patel Dr. C. N. Patel. "Review Of the Combination Dosage Form of Sitagliptin Phosphate Monohydrate and Dapagliflozin Propanediol Monohydrate as an Anti-Diabetic Agent." International Journal of Pharmaceutical Sciences 3, no. 5 (2025): 2020–27. https://doi.org/10.5281/zenodo.15391282.

Full text

Abstract:

Sitagliptin acting as Anti-Diabetic agent (Dipeptidyl peptidase-4 inhibitor) which boosts post prandial insulin release decreases Glucagon secretion and lower mean time as well as fasting blood glucose in type 2 diabetes mellitus. There is a strong rationale for combining a DPP-4i and a SGLT2i in patients with T2D because the two drugs exert different and complementary glucose-lowering effects. Dual therapy (initial combination or stepwise approach) is more potent than either monotherapy in patients treated with diet and exercise or already treated with metformin. This agent is used in combina

APA, Harvard, Vancouver, ISO, and other styles

10

Umapathysivam, Mahesh M., Bethany Morgan, Joshua M. Inglis, et al. "SGLT2 Inhibitor–Associated Ketoacidosis vs Type 1 Diabetes–Associated Ketoacidosis." JAMA Network Open 7, no. 3 (2024): e242744. http://dx.doi.org/10.1001/jamanetworkopen.2024.2744.

Full text

Abstract:

This cohort study examines the natural history and response to treatment of sodium glucose cotransporter 2 (SGLT2) inhibitor–associated ketoacidosis compared with that of type 1 diabetes–associated ketoacidosis.

APA, Harvard, Vancouver, ISO, and other styles

11

Sabirov, I. S., I. T. Murkamilov, and V. V. Fomin. "Potential mechanisms underlying cardiovascular protection by sodium glucose cotransporter 2 inhibitors (empagliflozin)." Complex Issues of Cardiovascular Diseases 10, no. 3 (2021): 79–89. http://dx.doi.org/10.17802/2306-1278-2021-10-3-79-89.

Full text

Abstract:

The presented literature review is devoted to the cardioprotective capabilities of a new class of antihyperglycemic drugs - sodium-glucose cotransporter 2 inhibitors (SGLT2), which improve glycemic control through an insulin-independent mechanism of action associated with an increase in urinary glucose excretion. The article presents the results of large-scale clinical trials on the use of SGLT2 inhibitors in patients with and without diabetes, and with cardiovascular diseases or multiple cardiovascular risk factors. A number of the most frequently discussed cardiac specific mechanisms mediate

APA, Harvard, Vancouver, ISO, and other styles

12

Vasilakou, Despoina, Thomas Karagiannis, Eleni Athanasiadou, et al. "Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes." Annals of Internal Medicine 159, no. 4 (2013): 262. http://dx.doi.org/10.7326/0003-4819-159-4-201308200-00007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Mazer, C. David, Amel Arnaout, Kim A. Connelly, et al. "Sodium-glucose cotransporter 2 inhibitors and type 2 diabetes." Current Opinion in Cardiology 35, no. 2 (2020): 178–86. http://dx.doi.org/10.1097/hco.0000000000000704.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Ametov, A. S., E. Yu Pashkova, E. N. Vengerova, U. P. Lyamtseva, and A. V. Bedina. "Diabetic Ketoacidos against the Background of Type 2 Sodium-Glucose Cotransporter Inhibitor Use in a Patient with Type 2 Diabetes Mellitus." Doctor.Ru 23, no. 8 (2024): 75–79. https://doi.org/10.31550/1727-2378-2024-23-8-75-79.

Full text

Abstract:

Aim. To demonstrate the outcome of type 2 sodium-glucose cotransporter (SGLT-2) inhibitor use in a young patient with newly diagnosed type 2 diabetes mellitus against the background of a limited amount of carbohydrates in the diet by developing of diabetic ketoacidosis (DKA). Key points. DKA is an acute life–threatening complication of diabetes mellitus, characterized by a complex of symptoms — hyperglycemia, hyperketonemia, metabolic acidosis. It develops in situations where the metabolic need for insulin significantly exceeds its level in the body. After the introduction of SGLT-2 inhibitors

APA, Harvard, Vancouver, ISO, and other styles

15

Sturov, N. V., S. V. Popov, N. K. Mamporia, and A. A. Mager. "Urinary tract infections in patients with type 2 diabetes mellitus with pharmacological glucosuria." Terapevticheskii arkhiv 92, no. 11 (2020): 106–9. http://dx.doi.org/10.26442/00403660.2020.11.000581.

Full text

Abstract:

Selective inhibitors of sodium-glucose cotransporter belong to a new class of drugs for the treatment of type 2 diabetes mellitus. The mechanism of their action is based on insulin-independent reduction of glucose reabsorption in the proximal renal tubules, which leads to stimulation of its excretion in the urine and, accordingly, to a decrease in the concentration of glucose in the blood plasma. Drugs of this group demonstrate effectiveness in the treatment of type 2 diabetes, but their use may be associated with an increased frequency of urinary tract infections. Pharmacological glucosuria,

APA, Harvard, Vancouver, ISO, and other styles

16

Davies, Claire. "SGLT2 inhibitors in type 2 diabetes: time to flozinate?" Practice Nursing 33, no. 11 (2022): 452–57. http://dx.doi.org/10.12968/pnur.2022.33.11.452.

Full text

Abstract:

Sodium-glucose cotransporter-2 (SGLT2) inhibitors have a wide range of benefits in people with insufficiently controlled type 2 diabetes. Claire Davies provides an overview of these drugs to support safe use in primary care Sodium-glucose cotransporter-2 (SGLT2) inhibitors, sometimes also referred to as ‘gliflozins’ or ‘flozins’, are an established class of medications used for the treatment of insufficiently controlled type 2 diabetes. This article provides a summary of everything nursing staff in primary care need to know about the use of SGLT2 inhibitors for type 2 diabetes to support safe

APA, Harvard, Vancouver, ISO, and other styles

17

Wang, Zhanguo, Ziyang Gao, Anqi Wang, et al. "Comparative oral and intravenous pharmacokinetics of phlorizin in rats having type 2 diabetes and in normal rats based on phase II metabolism." Food & Function 10, no. 3 (2019): 1582–94. http://dx.doi.org/10.1039/c8fo02242a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Levchuk, Nataliia. "Effect of sodium-dependent glucose cotransporter type 2 inhibitors on lipid metabolism in patients with diabetes mellitus (literature review)." JOURNAL OF THE NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE 29, no. 1-2 (2023): 5–21. http://dx.doi.org/10.37621/jnamsu-2023-1-2-1.

Full text

Abstract:

EFFECT OF SODIUM-DEPENDENT GLUCOSE COTRANSPORTER TYPE 2 INHIBITORS ON LIPID METABOLISM IN PATIENTS WITH DIABETES MELLITUS (literature review) Nataliia I. Levchuk, Olena I. Kovzun, Volodymyr M. Pushkarev, Mykola D. Tronko State Institution «V. P. Komisarenko Institute of Endocrinology and Metabolism of the National Academy of Medical Sciences of Ukraine», Vyshgorodska Str., 69, Kyiv 04114, Ukraine Resume. With diabetes, the metabolism, composition and ratio of lipids changes significantly. Lipids are important biological molecules that play an essential structural and physiological role in the

APA, Harvard, Vancouver, ISO, and other styles

19

Dumitru, Adriana, and Mihaela Posea. "Euglycemic Ketoacidosis Diagnosis and Treatment Protocol in Type 1 Diabetes Patient." Romanian Journal of Diabetes Nutrition and Metabolic Diseases 26, no. 3 (2019): 323–26. http://dx.doi.org/10.2478/rjdnmd-2019-0034.

Full text

Abstract:

Abstract Introduction. The introduction of sodium glucose cotransporter 2 inhibitors in the management of diabetes was an innovation in the treatment of this disease, considering the protective cardiovascular effect not only the ability of decreasing the plasma glucose. In Europe, this class of medication is approved for the treatment of type 2 diabetes and some of them (dapagliflozin and sotagliflozin) are also approved for use in certain patients with type 1 diabetes mellitus. These patients must have inadequate control of their blood glucose levels despite optimal insulin therapy. One of th

APA, Harvard, Vancouver, ISO, and other styles

20

Stinkens, Kirsten, and Chantal Mathieu. "Sodium-glucose Cotransporter 2 Inhibitors and Ketoacidosis – Clinical Implications in the Treatment of Patients with Type 2 Diabetes." European Endocrinology 12, no. 1 (2016): 33. http://dx.doi.org/10.17925/ee.2016.12.01.33.

Full text

Abstract:

The use of sodium-glucose cotransporter 2 inhibitors is associated with an increased risk of diabetic ketoacidosis. This risk has been reported in particular in off-label use of these agents in type 1 diabetes, but reports of risks in type 2 diabetes patients also exist. In type 2 diabetes ketoacidosis is rare and is present particularly in patients who have undergone prolonged starvation, serious infection, alcohol abuse or surgery. The pleiotropic advantages of sodium-glucose cotransporter 2 inhibitors do not outweigh the risk for a diabetic ketoacidosis, but caution is warranted.

APA, Harvard, Vancouver, ISO, and other styles

21

Bardhi, Olgert, Matthew D. Bloom, and Maryam Sattari. "Euglycaemic diabetic ketoacidosis in a patient with pancreatitis and type 2 diabetes on empagliflozin." BMJ Case Reports 15, no. 6 (2022): e247921. http://dx.doi.org/10.1136/bcr-2021-247921.

Full text

Abstract:

Sodium glucose cotransporter-2 (SGLT2) inhibitors are glucose-lowering drugs with proven efficacy in treating type 2 diabetes mellitus, and more recently, have been shown to improve heart failure outcomes in patients without diabetes. A rare complication of SGLT2 inhibitor use is the development of euglycaemic diabetic ketoacidosis (EDKA), characterised by euglycaemia (blood glucose level <250 mg/dL), metabolic acidosis (arterial pH <7.3 and serum bicarbonate <18 mEq/L), and ketonaemia. Given patients with EDKA do not present with the typical manifestations of diabetic ketoacidosis, i

APA, Harvard, Vancouver, ISO, and other styles

22

Coutu, Camille, Élisabeth Gaudreau, Lynette Israilian, Joëlle Latreille, and Viviane Lavigne. "Acidocétose euglycémique attribuable aux inhibiteurs du cotransporteur sodium-glucose de type 2 : savoir la prévenir, la reconnaître et la traiter." Pharmactuel 58, no. 1 (2025): 22–30. https://doi.org/10.63209/2025.1549.

Full text

Abstract:

Objectif : L’objectif du présent article est de discuter d’un effet indésirable rare, mais grave des inhibiteurs du cotransporteur sodium-glucose de type 2 (iSGLT2), soit l’acidocétose euglycémique. Nous passerons aussi en revue sa physiopathologie, sa détection, sa prise en charge et sa prévention. Sources des données et sélection des études : Une revue de la littérature scientifique publiée entre 2010 et 2024 dans des bases de données telles que PubMed et Google Scholar a été effectuée en utilisant et en reliant des mots clés comme diabetic ketoacidosis, diagnosis, euglycemic ketoacidosis, i

APA, Harvard, Vancouver, ISO, and other styles

23

Gorban, Vitaly V., and Ivan A. Gerasimenko. "The experience of successful use of dapagliflozin to manage adverse effects due to uncontrolled and long-term use of torasemide in a patient with type 2 diabetes mellitus with comorbid obesity. A clinical example." Clinical review for general practice 5, no. 4 (2024): 6–8. http://dx.doi.org/10.47407/kr2024.5.4.00413.

Full text

Abstract:

This article provides an example of a smooth and successful withdrawal of long-term and unjustified use of a diuretic (torasemide) in patients with type 2 diabetes mellitus with comorbid obesity by prescribing sodium-glucose cotransporter type 2 inhibitor (dapagliflozin).

APA, Harvard, Vancouver, ISO, and other styles

24

Ramakrishnan, Pavithra, Neetika Garg, Samantha Pabich, Didier A. Mandelbrot, and Kurtis J. Swanson. "Sodium-glucose cotransporter-2 inhibitor use in kidney transplant recipients." World Journal of Transplantation 13, no. 5 (2023): 239–49. http://dx.doi.org/10.5500/wjt.v13.i5.239.

Full text

Abstract:

Type 1 diabetes mellitus (T1DM) is one of the important causes of chronic kidney disease (CKD) and end-stage renal failure (ESRF). Even with the best available treatment options, management of T1DM poses significant challenges for clinicians across the world, especially when associated with CKD and ESRF. Substantial increases in morbidity and mortality along with marked rise in treatment costs and marked reduction of quality of life are the usual consequences of onset of CKD and progression to ESRF in patients with T1DM. Simultaneous pancreas-kidney transplant (SPK) is an attractive and promis

APA, Harvard, Vancouver, ISO, and other styles

25

Kaźmierski, Wojciech, Jakub Jurek, Paulina Lis, et al. "Sodium-Glucose Cotransporter-2 Inhibitors In Heart Failure." Prospects in Pharmaceutical Sciences 22, no. 3 (2024): 225–32. http://dx.doi.org/10.56782/pps.240.

Full text

Abstract:

Heart failure (HF) is a serious problem in a modern world, with increasing prevalence among ageing populations. The use of sodium-glucose cotransporter-2 (SGLT2) inhibitors, originally intended to treat type 2 diabetes, has revolutionised the treatment of HF. In this review article, we present the latest evidence on the mechanism of action of SGLT2 inhibitors, also called flosins, in HF. The primary mechanism of action of flosins is to reduce glucose reabsorption from glomerular filtration in the proximal renal tubule with a concomitant reduction in sodium reabsorption, leading to urinary gluc

APA, Harvard, Vancouver, ISO, and other styles

26

Cowie, Martin R. "Sodium–glucose cotransporter-2 inhibitors: where and when?" Future Cardiology 17, no. 3 (2021): 403–6. http://dx.doi.org/10.2217/fca-2020-0207.

Full text

Abstract:

Tweetable abstract Sodium–glucose cotransporter-2 inhibitors not only improve glycemic control in Type 2 diabetes mellitus but convincingly improve outcome for everyone with HFrEF and albuminuric kidney disease. Trials then license – now all we need is implementation

APA, Harvard, Vancouver, ISO, and other styles

27

Dixit, Divisha, Youngmin Yoon, Lucio R. Volino, and Rupal Patel Mansukhani. "Empagliflozin: A sodium–glucose cotransporter 2 inhibitor for treatment of type 2 diabetes." American Journal of Health-System Pharmacy 72, no. 22 (2015): 1943–54. http://dx.doi.org/10.2146/ajhp150071.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Tahrani, Abd A., and Anthony H. Barnett. "Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes." Diabetes Therapy 1, no. 2 (2010): 45–56. http://dx.doi.org/10.1007/s13300-010-0007-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Profili, Nicia I., Roberto Castelli, Antonio Gidaro, Roberto Manetti, Margherita Maioli, and Alessandro P. Delitala. "Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Heart Failure: An Update." Pharmaceuticals 17, no. 11 (2024): 1419. http://dx.doi.org/10.3390/ph17111419.

Full text

Abstract:

Diabetes mellitus and heart failure are two diseases that are commonly found together, in particular in older patients. High blood glucose has a detrimental effect on the cardiovascular system, and worse glycemic control contributes to the onset and the recrudesce of heart failure. Therefore, any specific treatment aimed to reduce glycated hemoglobin may, in turn, have a beneficial effect on heart failure. Sodium-glucose cotransporter-2 inhibitors have been initially developed for the treatment of type 2 diabetes mellitus, and their significant action is to increase glycosuria, which in turn c

APA, Harvard, Vancouver, ISO, and other styles

30

E, Shimizu, Takehisa Y, Bando H, Fujita M, Kusaka Y, and Yuu M. "Effective SGLT2 Inhibitor for Patient with Type 2 Diabetes Mellitus (T2DM) and Depression." SGLT2 inhibitors 2, S1 (2020): 26–32. http://dx.doi.org/10.36502/2020/droa.6160.

Full text

Abstract:

The case was a 55-year-old female patient with depression for 5 years and type 2 diabetes mellitus (T2DM) for 3 years. She has received anti-depressant and anti-hyperglycemic agents (OHAs). Approximately 1 year ago, her diabetic control became exacerbated without specific triggers. She was started to given Ipragliflozin L-Proline as Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor. After that, her glucose variability and depression had been improved. According to the previous reports, SGLT-2 inhibitors seem to have anti-depression efficacy for diabetes. The case has been followed up in detail,

APA, Harvard, Vancouver, ISO, and other styles

31

Bogdanffy, Matthew S., Robert F. Stachlewitz, Susan van Tongeren, et al. "Nonclinical Safety of the Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin." International Journal of Toxicology 33, no. 6 (2014): 436–49. http://dx.doi.org/10.1177/1091581814551648.

Full text

Abstract:

Empagliflozin, a selective inhibitor of the renal tubular sodium-glucose cotransporter 2, was developed for treatment of type 2 diabetes mellitus. Nonclinical safety of empagliflozin was studied in a battery of tests to support global market authorization. Safety pharmacology studies indicated no effect of empagliflozin on measures of respiratory or central nervous system function in rats or cardiovascular safety in telemeterized dogs. In CD-1 mouse, Wistar Han rat, or beagle dogs up to 13, 26, or 52 weeks of treatment, respectively, empagliflozin exhibited a toxicity profile consistent with s

APA, Harvard, Vancouver, ISO, and other styles

32

Winciorek, Joanna, Piotr Cyran, Anna Jaroszyńska, et al. "Euglycemic diabetes ketoacidosis associated with SGLT-2 inhibitors - review of case reports." Journal of Education, Health and Sport 68 (September 24, 2024): 55325. http://dx.doi.org/10.12775/jehs.2024.68.55325.

Full text

Abstract:

AIM: Sodium-glucose cotransporter 2 (SGLT-2) inhibitors have gained significant importance in the treatment of type 2 diabetes mellitus. One of the adverse effects while using SGLT-2 inhibitors is euglycemic ketoacidosis (euDKA) - acute life-threatening emergency. METHODS: The following review of case reports was based on articles published in 2023, obtained from the PubMed databases. Key search terms included “case report”, “sglt-2”, “sglt-2i”, “sodium-glucose cotransporter inhibitors”, “dka”. “eudka”, “euglycemic ketoacidosis”. RESULTS: In the literature, cases of euDKA correlated with the u

APA, Harvard, Vancouver, ISO, and other styles

33

Mkrtumyan, A. M., T. N. Markova, and N. K. Mishchenko. "Cardioprotective mechanisms of sodium-glucose cotransporter 2 inhibitors." Diabetes mellitus 24, no. 3 (2021): 291–99. http://dx.doi.org/10.14341/dm12541.

Full text

Abstract:

The findings of large-scale cardiovascular outcome trials have been demonstrated that sodium-glucose cotransporter 2 inhibitors (iSGLT-2) have shown beneficial cardiovascular effects. In this review proposed mechanisms underlying iSGLT-2-associated cardiovascular benefits have been discussed: haemodynamic and intracellular effects, including metabolic effects and electrolyte changes; and also, the effect on markers of cardiovascular disease (CVD). The hemodynamic effects of SGLT-2 are characterized by reduction of cardiac preload and afterload as a result of osmotic diuresis, a decrease in bl

APA, Harvard, Vancouver, ISO, and other styles

34

Blaschek, Wolfgang. "Natural Products as Lead Compounds for Sodium Glucose Cotransporter (SGLT) Inhibitors." Planta Medica 83, no. 12/13 (2017): 985–93. http://dx.doi.org/10.1055/s-0043-106050.

Full text

Abstract:

AbstractGlucose homeostasis is maintained by antagonistic hormones such as insulin and glucagon as well as by regulation of glucose absorption, gluconeogenesis, biosynthesis and mobilization of glycogen, glucose consumption in all tissues and glomerular filtration, and reabsorption of glucose in the kidneys. Glucose enters or leaves cells mainly with the help of two membrane integrated transporters belonging either to the family of facilitative glucose transporters (GLUTs) or to the family of sodium glucose cotransporters (SGLTs). The intestinal glucose absorption by endothelial cells is manag

APA, Harvard, Vancouver, ISO, and other styles

35

Yeoh, Huei Li, Marilyn Lee, Woei Jack Pan, and Hean Yee Ong. "Case of sodium–glucose cotransporter-2 inhibitor-associated euglycaemic diabetic ketoacidosis." BMJ Case Reports 14, no. 8 (2021): e235953. http://dx.doi.org/10.1136/bcr-2020-235953.

Full text

Abstract:

Following non-elective orthopaedic surgery, a 61-year-old man with poorly controlled type 2 diabetes mellitus on empagliflozin developed high anion gap metabolic acidosis in the high-dependency unit. Metabolic acidosis persisted despite intravenous sodium bicarbonate, contributing to tachycardia and a run of non-sustained ventricular tachycardia. He was euglycaemic throughout hospital admission. Investigations revealed elevated urine and capillary ketones, and a diagnosis of sodium–glucose cotransporter-2 inhibitor-associated euglycaemic diabetic ketoacidosis was made. He was treated with an i

APA, Harvard, Vancouver, ISO, and other styles

36

SM, Kuşkonmaz. "Diabetes Research Open Access: Sodium Glucose Cotransporter2 (SGLT2) Inhibitors." SGLT2 inhibitors 2, S1 (2020): 14. http://dx.doi.org/10.36502/2020/droa.6157.

Full text

Abstract:

Sodium glucose cotransporter 2 (SGLT2) inhibitors (SGLT2i) are a group of glycosuric drugs approved in the management of type 2 diabetes mellitus. They act on the sodium glucose cotransporter and inhibit renal glucose reabsorption. Canagliflozin dapagliflozin and empagliflozin are members of the SGLT2i group. SGLT2 is supposed to be unique to the kidney. Recent studies showed the benefits of these agents beyond and independent from glucose lowering. New guidelines emphasize these pleiotropic effects such as cardioprotective and renoprotective effects of SGLT2i and suggest them as first line or

APA, Harvard, Vancouver, ISO, and other styles

37

Vivian, Eva M. "Dapagliflozin: A new sodium–glucose cotransporter 2 inhibitor for treatment of type 2 diabetes." American Journal of Health-System Pharmacy 72, no. 5 (2015): 361–72. http://dx.doi.org/10.2146/ajhp140168.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Ramirez Tello, Edna M. Juarez, Menfil A. Orellana-Barrios, and Kenneth Nugent. "Sodium-glucose Cotransporter 2 Inhibitor–induced Diabetic Ketoacidosis in a Type 2 Diabetic Patient." American Journal of the Medical Sciences 351, no. 6 (2016): 634–35. http://dx.doi.org/10.1016/j.amjms.2016.03.014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Hedrington, Maka S., and Stephen N. Davis. "Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes." Expert Opinion on Drug Metabolism & Toxicology 11, no. 4 (2015): 613–23. http://dx.doi.org/10.1517/17425255.2015.1009893.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Siao, Wun-Zhih, Tsung-Kun Lin, Jing-Yang Huang, Chin-Feng Tsai, and Gwo-Ping Jong. "The association between sodium-glucose cotransporter 2 inhibitors and incident dementia: A nationwide population-based longitudinal cohort study." Diabetes and Vascular Disease Research 19, no. 3 (2022): 147916412210981. http://dx.doi.org/10.1177/14791641221098168.

Full text

Abstract:

Background The association of the use of sodium-glucose cotransporter 2 (SGLT2) inhibitor and incident dementia remains unclear. This study aimed to evaluate the risk of incident dementia with the use of SGLT2 inhibitor. Methods This is a population-based cohort study utilizing Taiwan’s National Health Insurance Research Database. Each patient who took SGLT2 inhibitors was assigned to the SGLT2 inhibitor group, whereas 1:1 propensity score-matched randomly selected patients who were nonusers of SGLT2 inhibitors were assigned to the non-SGLT2 inhibitor group. The study outcome was incident deme

APA, Harvard, Vancouver, ISO, and other styles

41

Neuen, Brendon L., David Z. Cherney, Meg J. Jardine, and Vlado Perkovic. "Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering." Canadian Medical Association Journal 191, no. 41 (2019): E1128—E1135. http://dx.doi.org/10.1503/cmaj.190047.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Nappi, Felice, Antonietta La Verde, Giovanni Carfora, et al. "Nephrology Consultation for Severe SGLT2 Inhibitor-Induced Ketoacidosis in Type 2 Diabetes: Case Report." Medicina 55, no. 8 (2019): 462. http://dx.doi.org/10.3390/medicina55080462.

Full text

Abstract:

Euglycemic diabetic ketoacidosis (euDKA) related to sodium-glucose cotransporter 2 inhibitor (SGLT2-I), despite being reported as consistent, though infrequent, adverse effect in all trials on SGLT2-I in type 2 diabetes mellitus (T2D), still remains poorly known in the real world. On the other hand, the use of this new class of antihyperglycemic agents is expected to increase based on the recent solid evidence of remarkable cardiorenal protection. Therefore, improving awareness on risk factors, diagnosis, and treatment of euDKA is essential to allow correct implementation of SGLT2-I in clinica

APA, Harvard, Vancouver, ISO, and other styles

43

Baek, Jong Ha, Tae Jung Oh, Ju-Young Moon, et al. "The Effect of Long-term Sodium-glucose Cotransporter 2 Inhibitor Treatment on Renal Function in the Patients with Type 2 Diabetes." Korean Journal of Medicine 95, no. 4 (2020): 236–43. http://dx.doi.org/10.3904/kjm.2020.95.4.236.

Full text

Abstract:

Chronic kidney disease is developed commonly in type 2 diabetes mellitus (T2DM) and is the most common cause of end-stage renal disease and related cardiovascular complications. Meanwhile, despite the current standard of care including optimized glucose control and the use of single-agent blockade of the renin-angiotensin-aldosterone system (RAAS), patients with T2DM remain at increased risk for death and complications from cardiorenal causes. The recent studies using sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown not only glucose lowering effect, but also a reduction in blood pr

APA, Harvard, Vancouver, ISO, and other styles

44

Ritchie, Duncan Taylor, and James Dixon. "SGLT-2 inhibitor associated euglycaemic diabetic ketoacidosis in an orthopaedic trauma patient." BMJ Case Reports 15, no. 9 (2022): e250233. http://dx.doi.org/10.1136/bcr-2022-250233.

Full text

Abstract:

Euglycaemic diabetic ketoacidosis is a serious but rare adverse effect of treatment with sodium-glucose cotransporter-2 (SGLT-2) inhibitors. A man in his 60s with type 2 diabetes mellitus underwent total hip replacement for an intracapsular neck of femur fracture. His SGLT-2 inhibitor was continued perioperatively and blood glucose levels were normal throughout the admission. A diagnosis of severe euglycaemic diabetic ketoacidosis was made in the operating theatre which required treatment in a critical care unit. This resulted in increased morbidity due to decreased postoperative mobilisation

APA, Harvard, Vancouver, ISO, and other styles

45

Perry, Rachel J., and Gerald I. Shulman. "Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks." Journal of Biological Chemistry 295, no. 42 (2020): 14379–90. http://dx.doi.org/10.1074/jbc.rev120.008387.

Full text

Abstract:

In a healthy person, the kidney filters nearly 200 g of glucose per day, almost all of which is reabsorbed. The primary transporter responsible for renal glucose reabsorption is sodium-glucose cotransporter-2 (SGLT2). Based on the impact of SGLT2 to prevent renal glucose wasting, SGLT2 inhibitors have been developed to treat diabetes and are the newest class of glucose-lowering agents approved in the United States. By inhibiting glucose reabsorption in the proximal tubule, these agents promote glycosuria, thereby reducing blood glucose concentrations and often resulting in modest weight loss.

APA, Harvard, Vancouver, ISO, and other styles

46

Katerenchuk, V. I. "The effect of modern hypoglycemic therapy on the course of chronic kidney disease in patients with type 2 diabetes mellitus." INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) 17, no. 8 (2022): 624–32. http://dx.doi.org/10.22141/2224-0721.17.8.2021.246795.

Full text

Abstract:

The article presents the literature review of the possibilities of modern antidiabetic therapy in the prevention of chronic kidney disease in patients with type 2 diabetes mellitus. The mechanisms of development and features of kidney disease in type 2 diabetes mellitus are described. The results of most recent clinical trials for studying the possibility of nephroprotection with new groups of hypoglycemic agents are reviewed: dipeptidyl peptidase-4 inhi-bitors, glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors. The advantages of usage and the nephroprotectiv

APA, Harvard, Vancouver, ISO, and other styles

47

Lukito, Johan Indra. "Antidiabetik Oral Kombinasi Penghambat DPP-4 dan Penghambat SGLT-2." Cermin Dunia Kedokteran 48, no. 12 (2021): 692–95. http://dx.doi.org/10.55175/cdk.v48i12.157.

Full text

Abstract:

Dalam tatalaksana diabetes melitus tipe 2, terapi kombinasi dua obat antidiabetik disarankan jika dengan monoterapi gagal mencapai target kontrol glikemik. Pemilihan jenis obat antidiabetik tergantung kondisi pasien dan profil obat. Kombinasi obat antidiabetik oral golongan penghambat DPP-4 (dipeptidyl peptidase-4) dan penghambat SGLT-2 (sodium-glucose cotransporter type 2) dapat menjadi salah satu pilihan. Combination of two antidiabetic drugs is recommended in the management of type 2 diabetes mellitus if monotherapy fails to achieve glycemic control targets. Choice of antidiabetic dru

APA, Harvard, Vancouver, ISO, and other styles

48

Ishmaev, D. A., M. S. Vasileva, and D. V. Duplyakov. "Effect of Sodium-Glucose Cotransporter Type 2 Inhibitors on The Development and Course of Atrial Fibrillation." Russian Archives of Internal Medicine 15, no. 1 (2025): 17–23. https://doi.org/10.20514/2226-6704-2025-15-1-17-23.

Full text

Abstract:

Atrial fibrillation is one of the most common heart rhythm disorders associated with an increased risk of stroke, cardiovascular mortality and hospitalizations. The development of arrhythmias is influenced by a number of risk factors, including arterial hypertension, chronic heart failure, coronary heart disease and endocrine disorders. New guidelines from the European Society of Cardiology (2024) emphasize the importance of managing risk factors to improve treatment efficacy and prognosis in patients with atrial fibrillation. Sodium-glucose cotransporter type 2 inhibitors (gliflozins), origin

APA, Harvard, Vancouver, ISO, and other styles

49

Rozado, José, Daniel García Iglesias, Miguel Soroa, et al. "Sodium-Glucose Cotransporter-2 Inhibitors at Discharge from Cardiology Hospitalization Department: Decoding A New Clinical Scenario." Journal of Clinical Medicine 9, no. 8 (2020): 2600. http://dx.doi.org/10.3390/jcm9082600.

Full text

Abstract:

Sodium-glucose cotransporter-2 inhibitors (SGLT-2 inhibitors) are new glucose-lowering drugs (GLDs) with demonstrated cardiovascular benefits in patients with heart disease and type-2 diabetes mellitus (T2DM). However, their safety and efficacy when prescribed at hospital discharge are unexplored. This prospective, observational, longitudinal cohort study included 104 consecutive T2DM patients discharged from the cardiology department between April 2018 and February 2019. Patients were classified based on SGLT-2 inhibitor prescription and adjusted by propensity-score matching. The safety outco

APA, Harvard, Vancouver, ISO, and other styles

50

Yanai, Hidekatsu. "Dipeptidyl Peptidase-4 Inhibitor Versus Sodium-Glucose Cotransporter-2 Inhibitor in the Management of Type 2 Diabetes." Journal of Endocrinology and Metabolism 9, no. 5 (2019): 117–19. http://dx.doi.org/10.14740/jem609.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!